Implicity, a European leader in remote monitoring of implantable cardiac devices and remote patient care, announced at the end of April a €21 million Series A financing round from Crédit Mutuel Innovation and Bpifrance, as well as BNP Paribas Développement and historical investors Serena Capital, XAnge and Karista. This investment will allow the company to accelerate the deployment of its AI-based technology and to develop new medical software. Implicity is a digital MedTech start-up in the field of cardiology. Its objective is to improve the efficiency of remote cardiac monitoring and to democratize it. Co-founded by Arnaud Rosier, electrophysiologist and doctor in health informatics, convinced that remote monitoring could improve patient care and optimize their vital prognosis, and David Perlmutter in 2016, signal processing engineer, currently in charge of R&D. Today, Implicity is a leader in the remote monitoring of implantable cardiac electronic devices (ICDs) in France and internationally, thanks to its remote monitoring platform that covers more than 60,000 patients in 100 medical institutions in Europe and the United States. Implicity is the winner of the first Health Data Hub call for projects, giving access to the Health Data Club's health database as well as to the National Health Data System's database. Implicity develops medical software devices based on artificial intelligence algorithms for predictive cardiology and to optimize the functioning of medical teams. The start-up has recently received approval from the Federal and Drug Administration (FDA) to operate a new AI algorithm for analyzing ECG events from implantable cardiac monitors. Arnaud Rosier explains:.
"This funding round opens an exciting new chapter for Implicity. As we see everywhere that remote monitoring teams are grappling with an increasing amount of data from connected devices, the need for a universal remote platform is now widely recognized as paramount for all players in the field. With the support of investors, we plan to increase our presence in the United States and expand into new market opportunities. In order to democratize remote cardiac care, our mission is to provide healthcare professionals with the best technology available to monitor all cardiac patients."

Develop new software for medicine and accelerate international deployment

The fundraising will accelerate the international rollout of Implicity's AI-based technology, particularly in the United States, but also develop new medical software devices, and thus enable Simplicity to maintain its leadership position. Delphine Cardi, Director of Investments at Crédit Mutuel innovation, assures:
"We are very pleased to support the commercial expansion of Implicity's remote monitoring platform, which enables cardiologists to offer their patients better quality monitoring thanks to an ingenious integration of data from remote cardiac monitoring devices. The company is already on a solid growth trajectory in the US and Europe. With this investment, we are giving it the means to build on this momentum and develop next-generation offerings geared towards heart disease prevention."
Chahra Louafi, Director of the Autonomous Patients Fund at Bpifrance, adds:
"We are impressed by Implicity's current success in the international market. We believe the company has the potential to become a world-class leader in the field of remote cardiac monitoring. This investment will help accelerate adoption in all regions in 2022, especially in the U.S. which is a very large market opportunity."
Translated from Implicity, start-up spécialisée dans la télésurveillance des dispositifs cardiaques, annonce une levée de fonds de 21 millions d'euros

Our articles will then appear first in Google Top Stories.